PriceTargets.com logo

PPD - PPD Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$47.28 As of 12/8/2021 01:00 AM ET
+0 (0.00%)
Get New PPD Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PPD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PPD

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for PPD in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $47.28.

This chart shows the closing price for PPD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in PPD. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/31/2021Deutsche Bank AktiengesellschaftUpgradeBuy$47.00Low
4/28/2021JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Neutral$48.00Low
4/26/2021Credit Suisse GroupReiterated RatingOutperform ➝ Neutral$42.00 ➝ $47.50Low
4/26/2021Jefferies Financial GroupReiterated RatingBuy ➝ HoldN/A
4/22/2021KeyCorpReiterated RatingOverweight ➝ Sector Weight$40.00Low
4/22/2021William BlairReiterated RatingOutperform ➝ Market PerformLow
4/22/2021Deutsche Bank AktiengesellschaftReiterated RatingBuy ➝ Hold$39.00 ➝ $47.00Low
4/21/2021Robert W. BairdReiterated RatingOutperform ➝ Neutral$48.00N/A
4/20/2021Jefferies Financial GroupDowngradeBuy ➝ HoldLow
4/19/2021CitigroupDowngradeBuy ➝ NeutralLow
4/19/2021MizuhoDowngradeBuy ➝ NeutralLow
4/19/2021Credit Suisse GroupDowngradeOutperform ➝ Neutral$42.00 ➝ $47.50Low
4/16/2021Truist FinancialDowngradeBuy ➝ HoldLow
4/16/2021Evercore ISIDowngradeOutperformLow
4/16/2021Truist FinancialReiterated RatingBuy ➝ HoldMedium
4/16/2021William BlairDowngradeOutperform ➝ Market PerformMedium
4/16/2021Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$39.00 ➝ $47.00Medium
4/15/2021Robert W. BairdDowngradeOutperform ➝ Neutral$48.00High
3/2/2021BarclaysInitiated CoverageOverweight$42.00Low
2/25/2021CitigroupBoost Target$40.00 ➝ $42.00Low
2/25/2021Deutsche Bank AktiengesellschaftBoost TargetBuy$38.00 ➝ $39.00Medium
10/29/2020Deutsche Bank AktiengesellschaftBoost TargetBuy$33.00 ➝ $38.00Low
10/12/2020Truist FinancialInitiated CoverageBuy$42.00Medium
9/22/2020MizuhoBoost TargetBuy$35.00 ➝ $38.00Medium
9/21/2020Robert W. BairdBoost TargetAverage ➝ Outperform$36.00 ➝ $40.00Medium
9/15/2020KeyCorpBoost TargetOverweight$35.00 ➝ $37.00Medium
8/6/2020MizuhoBoost TargetBuy$29.00 ➝ $35.00Low
8/6/2020CitigroupBoost TargetIn-Line ➝ Buy$31.00 ➝ $37.00Low
8/5/2020Morgan StanleyBoost TargetOverweight$30.00 ➝ $35.00High
8/5/2020Credit Suisse GroupBoost TargetOutperform$30.00 ➝ $35.00High
6/4/2020KeyCorpInitiated CoverageOverweight$35.00High
5/12/2020UBS GroupBoost TargetBuy$32.00 ➝ $35.00Medium
5/12/2020Deutsche Bank AktiengesellschaftLower TargetBuy$33.00 ➝ $31.00Low
5/8/2020Morgan StanleyBoost TargetOverweight$26.00 ➝ $30.00High
5/8/2020MizuhoBoost TargetBuy$22.00 ➝ $29.00High
5/7/2020Credit Suisse GroupLower TargetOutperform$32.00 ➝ $30.00Medium
4/28/2020UBS GroupLower TargetBuy$34.00 ➝ $32.00Low
4/9/2020CitigroupLower TargetBuy$34.00 ➝ $26.00Medium
4/3/2020MizuhoLower TargetBuy$30.00 ➝ $22.00High
3/26/2020BarclaysLower TargetOverweight$33.00 ➝ $30.00Low
3/23/2020Jefferies Financial GroupUpgradeHold ➝ Buy$30.50 ➝ $20.00Medium
3/2/2020Jefferies Financial GroupInitiated CoverageHold$30.50High
3/2/2020Deutsche Bank AktiengesellschaftInitiated CoverageBuy$33.00High
3/2/2020JPMorgan Chase & Co.Initiated CoverageOverweight$35.00High
3/2/2020Bank of AmericaInitiated CoverageBuy$33.00High
3/2/2020UBS GroupInitiated CoverageBuy$34.00High
3/2/2020CitigroupInitiated CoverageBuy$34.00High
3/2/2020Robert W. BairdInitiated CoverageOutperform$35.00High
3/2/2020Morgan StanleyInitiated CoverageOverweight$34.00High
3/2/2020Evercore ISIInitiated CoverageOutperform$33.00High
3/2/2020Credit Suisse GroupInitiated CoverageOutperform$32.00High
3/2/2020MizuhoInitiated CoverageBuy$32.00High
3/2/2020William BlairInitiated CoverageOutperformHigh
3/2/2020The Goldman Sachs GroupInitiated CoverageBuy$34.00High
3/2/2020BarclaysInitiated CoverageOverweight$33.00High
(Data available from 4/23/2019 forward)

News Sentiment Rating

-0.61 (Sell)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 27 positive mentions
  • 8 negative mentions
  • 10 very negative mentions
Mentions as of
9/26/2023
  • 1 very positive mentions
  • 19 positive mentions
  • 12 negative mentions
  • 19 very negative mentions
Mentions as of
10/26/2023
  • 2 very positive mentions
  • 23 positive mentions
  • 16 negative mentions
  • 14 very negative mentions
Mentions as of
11/25/2023
  • 1 very positive mentions
  • 29 positive mentions
  • 12 negative mentions
  • 14 very negative mentions
Mentions as of
12/25/2023
  • 3 very positive mentions
  • 23 positive mentions
  • 14 negative mentions
  • 13 very negative mentions
Mentions as of
1/24/2024
  • 3 very positive mentions
  • 22 positive mentions
  • 14 negative mentions
  • 14 very negative mentions
Mentions as of
2/23/2024
  • 2 very positive mentions
  • 19 positive mentions
  • 20 negative mentions
  • 22 very negative mentions
Mentions as of
3/24/2024
  • 2 very positive mentions
  • 28 positive mentions
  • 23 negative mentions
  • 27 very negative mentions
Mentions as of
4/23/2024

Current Sentiment

  • 2 very positive mentions
  • 28 positive mentions
  • 23 negative mentions
  • 27 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

PPD logo
PPD, Inc., together with its subsidiaries, provides drug development services to the biopharmaceutical industry worldwide. The company operates through two segments, Clinical Development Services and Laboratory Services. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri-and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company has a collaboration with Science 37 to design, build, test, implement, and execute digital trials using Science 37's DCT SaaS-based technology platform. PPD, Inc. was founded in 1985 and is headquartered in Wilmington, North Carolina.
Read More

Today's Range

Now: $47.28
Low: $47.28
High: $47.28

50 Day Range

MA: $47.27
Low: $47.10
High: $47.41

52 Week Range

Now: $47.28
Low: $31.54
High: $47.41

Volume

N/A

Average Volume

1,905,567 shs

Market Capitalization

$16.61 billion

P/E Ratio

47.28

Dividend Yield

N/A

Beta

1.96

Frequently Asked Questions

What sell-side analysts currently cover shares of PPD?

The following Wall Street research analysts have issued stock ratings on PPD in the last year:
View the latest analyst ratings for PPD.

What is the current price target for PPD?

0 Wall Street analysts have set twelve-month price targets for PPD in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for PPD in the next year.
View the latest price targets for PPD.

What is the current consensus analyst rating for PPD?

PPD currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for PPD.

What other companies compete with PPD?

Other companies that are similar to PPD include Charles River Laboratories International, Incyte, Medpace, PRA Health Sciences and ICON Public. Learn More about companies similar to PPD.

How do I contact PPD's investor relations team?

PPD's physical mailing address is 929 NORTH FRONT STREET, WILMINGTON NC, 28401. The company's listed phone number is 910-251-0081 and its investor relations email address is [email protected]. The official website for PPD is www.ppdi.com. Learn More about contacing PPD investor relations.